Perivan welcomes ReNeuron Group to our Annual Report portfolio
June 2023
Headquartered in Bridgend UK, ReNeuron Group is an AIM listed global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop ‘off the shelf’ stem cell treatments, without the need for immunosuppressive drugs. The Company’s lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
The Company is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
Annual Report
The Perivan shareholder communications team was delighted to be appointed to produce the latest Annual Report, which was successfully published and posted to shareholders on 16th June 2023.
To view the full Annual Report, click here.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.
